Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Perspective and Pathogenesis
-
23 min
1. Expanding frontiers of cerebrovascular disease- Prof. Vladimir Hachinski
-
32 min
2. Basic anatomy, physiology and pathophysiology of the cerebral circulation for the physician- Prof. Jean-Claude Baron
-
43 min
3. Pathophysiology of cerebral ischemia- Prof. Wolf-Dieter Heiss
-
20 min
4. Intracerebral hemorrhages: causes and clinical findings- Prof. Louis Caplan
-
40 min
5. Subarachnoid hemorrhage (SAH)- Prof. R. Loch Macdonald
- Diagnosis
-
32 min
6. Clinical diagnosis of stroke and subtypes- Prof. Louis Caplan
-
30 min
7. The investigation of stroke- Dr. Bart Demaerschalk
- Treatment
-
35 min
8. Acute therapy of stroke and reperfusion treatments- Prof. Brian Silver
-
39 min
9. Subarachnoid hemorrhage diagnosis and management- Prof. Gary K. Steinberg
-
26 min
10. Stroke-induced heart injury- Dr. Luciano A. Sposato
- Rehabilitation
-
37 min
11. Stroke rehabilitation: principles of stroke- Prof. Robert Teasell
-
27 min
12. Stroke rehabilitation: therapies and treatments- Prof. Robert Teasell
- Prevention
-
23 min
13. Lifestyle and nutrition in stroke prevention- Prof. J. David Spence
-
40 min
- Special Topics
-
54 min
15. Pediatric stroke: cerebrovascular injury in the developing brain- Prof. Adam Kirton
-
43 min
16. Stroke in women: epidemiology, risk and prevention- Prof. Cheryl Bushnell
-
25 min
17. Transient ischemic attack and cognition- Dr. Jennifer Mandzia
-
31 min
18. Vascular cognitive impairment- Prof. Eric E. Smith
-
34 min
19. Atrial fibrillation, anticoagulation and vitamins for homocysteine- Prof. J. David Spence
-
41 min
20. Stroke in the young adult- Prof. Jeffrey Saver
-
16 min
21. Stroke in the young- Dr. Gyan Kumar
-
23 min
22. Convergence and joint prevention of stroke and dementia- Prof. Vladimir Hachinski
- Archived Lectures *These may not cover the latest advances in the field
-
55 min
23. Vascular cognitive impairment- Dr. John Bowler
-
32 min
24. Pediatric stroke- Dr. Gabrielle deVeber
-
36 min
25. The deteriorating stroke- Prof. Werner Hacke
-
27 min
26. General management- Prof. Bo Norrving
-
35 min
27. The treatment of stroke: specific management - thrombolysis plus- Prof. Nils Wahlgren
-
42 min
28. Rehabilitation: the chronic phase- Prof. Lalit Kalra
-
61 min
29. Prevention: management of risk and protective factors- Prof. Graeme Hankey
-
30 min
30. Medical therapy for secondary prevention of ischemic stroke- Prof. Larry Goldstein
-
34 min
31. Subarachnoid haemorrhage- Prof. Jan van Gijn
-
35 min
32. Controversies in stroke- Prof. Stephen Davies
- Prof. Geoffrey Donnan
-
35 min
33. Medical and surgical stroke- Prof. Carlos Kase
-
35 min
34. The urgency of stroke prevention after TIA- Prof. S. Claiborne Johnston
-
54 min
35. Carotid endarterectomy, angioplasty and stenting- Prof. Martin Brown
-
42 min
36. The clinical diagnosis of stroke and stroke subtypes- Prof. Louis Caplan
Printable Handouts
Navigable Slide Index
- Introduction
- Neurological symptoms
- Six issues following the onset of symptoms
- Pathological and aetiological subtypes of stroke
- Treatment strategies for ischaemic stroke
- The prevention of recurrent ischemic events
- Risk of recurrent ischaemic stroke
- Survival and vascular event risk after TIA
- Causes of recurrent ischaemic stroke
- Recurrent atherothromboembolic events prevention
- Carotid revascularisation
- Vascular risk factor control
- Causal risk factors for recurrent stroke
- Blood pressure as a major risk factor
- Increase in BP is associated with stroke
- Lowering BP reduces the risk of stroke (1)
- Lowering BP reduces the risk of stroke (2)
- BP reduction and secondary prevention of stroke
- HOPE study: inclusion criteria
- Reduction in stroke, MI or vascular death
- HOPE study: subgroup analyses
- HOPE study: outcome events
- Consistent reduction in risk of stroke with ramipril
- PROGRESS trial: design
- PROGRESS trial: blood pressure differences
- PROGRESS trial: stroke risk reduction
- BP-lowering effect on risk of recurrent stroke (1)
- BP-lowering effect on risk of recurrent stroke (2)
- Combination therapy is more effective
- How low should BP be lowered?
- PROGRESS: Effect of combination therapy
- Lowering BP by non-pharmacological intervention
- AHA/ASA guidelines: hypertension
- Second major risk factor: hyperlipidemia
- Effects of statins on stroke (1)
- Effects of statins on stroke (2)
- Statins in patients with a history of stroke
- Vascular events by lipid concentration
- Effects of simvastatin allocation on stroke
- Reduction of LDL-C and relative risk of stroke
- Dietary and lifestyle modifications
- AHA/ASA stroke-prevention guidelines: Lipids (1)
- AHA/ASA stroke-prevention guidelines: Lipids (2)
- AHA/ASA stroke-prevention guidelines: Lipids(3)
- Diabetes Mellitus as a risk factor
- Impact of Ramipril on stroke in HOPE trial
- Statin treatment in diabetes patients
- LDL-C reduction effect on major vascular events (1)
- LDL-C reduction effect on major vascular events (2)
- LDL-C reduction effect on major vascular events (3)
- HbA1c reduction associated with stroke reduction
- AHA/ASA stroke prevention guidelines-diabetes
- Smoking as a risk factor
- Smoking and risk of stroke
- Increasing odds of MI with increased smoking
- AHA/ASA stroke prevention guidelines - smoking
- Alcohol intake as a risk factor
- Alcohol and risk of stroke in men (1)
- Alcohol and risk of stroke in men (2)
- Greater intake of alcohol
- Alcohol consumption and risk of stroke
- AHA/ASA stroke prevention guidelines - alcohol
- Is obesity a risk factor for stroke?
- Body mass index and risk of stroke (1)
- Body mass index and risk of stroke (2)
- AHA/ASA stroke prevention guidelines - obesity
- Can physical activity reduce the risk of stroke?
- Physical activity and risk of stroke
- Leisure time physical activity and risk of stroke
- Active commuting and risk of stroke
- AHA/ASA guidelines - physical activity
- Effect of lowering homocysteine on IHD and stroke
- Folic acid and relative risk of stroke
- AHA/ASA guidelines - hyperhomocystinaemia
- AHA/ASA guidelines - Antiphospholipid antibodies
- Increased risk of stroke with hormone therapy
- AHA/ASA guidelines - hormone therapy
- Cardioegenic embolism causes recurrent strokes
- Atrial fibrillation as a cardioembolic cause
- Hemorrhagic transformation of cerebral infarction
- Heparin and recurrent stroke rates
- Effect of anticoagulants vs. placebo or aspirin
- The long-term benefits of anticoagulation
- Outcome among AF patients after TIA or IS
- Aspirin effect on stroke or systemic embolism
- Warfarin effect on stroke or systemic embolism
- Effect of Warfain compared with Aspirin
- Optimal INR in nonrheumatic AF
- What is the appropriate treatment for each patient?
- Clinical predictors of ischaemic stroke in AF
- Echocardiograph helps to re-stratify the patient
- New anticoagulants
- AHA/ASA guidelines - atrial fibrillation
- AHA/ASA guidelines - acute MI and LFT
- AHA/ASA guidelines - cardiomyopathy
- AHA/ASA guidelines - valvular heart disease
- AHA/ASA guidelines - mitral valve prolapse
- AHA/ASA guidelines - prosthetic heart valves
- Patients with patent foramen ovale
- AHA/ASA guidelines - patent foramen ovale
- Summary
Topics Covered
- Patients with ischaemic stroke are at high risk of recurrent vascular events
- One strategy to reduce the risk of recurrent events is controlling causal risk factors
- Effective strategies include stopping smoking, lowering blood pressure and blood cholesterol, minimising alcohol and salt consumption and optimizing glycosylated haemoglobin, body weight and physical activity
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hankey, G. (2008, October 27). Prevention: management of risk and protective factors [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/WRWW1985.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Graeme Hankey has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
